There is one clinical trial.
Evaluate HACOR socre utility and efficacy in predicting NIV and/or CPAP failure in patients with COVID-19 associated respiratory failure. Propose adaptations to HACOR score based on the "state of art" of COVID-19
Description: Analyze if HACOR score is effective in predicting nonivasive ventilation failure in COVID-19 associated respiratory failureMeasure: HACOR score efficacy Time: 1 hour after initation of CPAP or NIV
Description: Analyze the role of possible variables to be added to HACOR score in order to improve efficay in COVID-19 patientsMeasure: HACOR score addaptation Time: 1 - 2 weeks
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports